561 related articles for article (PubMed ID: 16932427)
1. Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
Baylis C
Nat Clin Pract Nephrol; 2006 Apr; 2(4):209-20. PubMed ID: 16932427
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide deficiency in chronic kidney disease.
Baylis C
Am J Physiol Renal Physiol; 2008 Jan; 294(1):F1-9. PubMed ID: 17928410
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
Böger RH
J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
[TBL] [Abstract][Full Text] [Related]
4. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
[TBL] [Abstract][Full Text] [Related]
5. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems.
Palm F; Onozato ML; Luo Z; Wilcox CS
Am J Physiol Heart Circ Physiol; 2007 Dec; 293(6):H3227-45. PubMed ID: 17933965
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
7. Renoprotective effects of melatonin in young spontaneously hypertensive rats with L-NAME.
Cheng MC; Wu TH; Huang LT; Tain YL
Pediatr Neonatol; 2014 Jun; 55(3):189-95. PubMed ID: 24268813
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethylarginine, endothelial dysfunction and renal disease.
Aldámiz-Echevarría L; Andrade F
Int J Mol Sci; 2012; 13(9):11288-11311. PubMed ID: 23109853
[TBL] [Abstract][Full Text] [Related]
9. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression.
Selley ML
J Affect Disord; 2004 Jun; 80(2-3):249-56. PubMed ID: 15207938
[TBL] [Abstract][Full Text] [Related]
10. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine.
Feng M; Liu L; Guo Z; Xiong Y
Eur J Pharmacol; 2008 Apr; 584(1):49-56. PubMed ID: 18342305
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of asymmetric dimethylarginine.
Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
[TBL] [Abstract][Full Text] [Related]
12. Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy.
Wetzel MD; Gao T; Stanley K; Cooper TK; Morris SM; Awad AS
Am J Physiol Renal Physiol; 2020 Feb; 318(2):F509-F517. PubMed ID: 31904280
[TBL] [Abstract][Full Text] [Related]
13. The endothelium as a target in renal diseases.
Zoccali C
J Nephrol; 2007; 20 Suppl 12():S39-44. PubMed ID: 18050141
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine, an endogenous NOS inhibitor, is actively metabolized in rat erythrocytes.
Yokoro M; Suzuki M; Murota K; Otsuka C; Yamashita H; Takahashi Y; Tsuji H; Kimoto M
Biosci Biotechnol Biochem; 2012; 76(7):1334-42. PubMed ID: 22785485
[TBL] [Abstract][Full Text] [Related]
15. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide synthase derangements and hypertension in kidney disease.
Baylis C
Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):1-6. PubMed ID: 22048724
[TBL] [Abstract][Full Text] [Related]
17. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
[TBL] [Abstract][Full Text] [Related]
18. The biology and therapeutic potential of the DDAH/ADMA pathway.
Arrigoni F; Ahmetaj B; Leiper J
Curr Pharm Des; 2010; 16(37):4089-102. PubMed ID: 21247398
[TBL] [Abstract][Full Text] [Related]
19. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease.
Böger RH; Zoccali C
Atheroscler Suppl; 2003 Dec; 4(4):23-8. PubMed ID: 14664899
[TBL] [Abstract][Full Text] [Related]
20. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease.
Matsumoto Y; Ueda S; Yamagishi S; Matsuguma K; Shibata R; Fukami K; Matsuoka H; Imaizumi T; Okuda S
J Am Soc Nephrol; 2007 May; 18(5):1525-33. PubMed ID: 17409314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]